Effects of rosiglitazone on serum paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus

被引:12
作者
Atamer, Y. [1 ]
Atamer, A. [2 ]
Can, A. S. [3 ]
Hekimoglu, A. [4 ]
Ilhan, N. [5 ]
Yenice, N. [6 ]
Kocyigit, Y. [7 ]
机构
[1] Dicle Univ, Fac Med, Dept Med Biochem, Diyarbakir, Turkey
[2] Haydarpas Numune Training & Res Hosp, Minist Hlth, Dept Internal Med, Div Gastroenterol, TR-34668 Istanbul, Turkey
[3] Yalova Univ, Termal Profess Sch, Yalova, Turkey
[4] Dicle Univ, Fac Med, Dept Pharmacol, Diyarbakir, Turkey
[5] Firat Univ, Fac Med, Dept Med Biochem, TR-23169 Elazig, Turkey
[6] Harran Univ, Fac Med, Dept Internal Med, Div Gastroenterol, Urfa, Turkey
[7] Dicle Univ, Fac Med, Dept Physiol, Diyarbakir, Turkey
关键词
Rosiglitazone; Diabetes mellitus type 2; Paraoxonase; Lipoproteins; Homocysteine; Lipid peroxidation; OXIDATIVE STRESS; CARDIOVASCULAR-DISEASE; HOMOCYSTEINE; RISK; ATHEROSCLEROSIS; EXPRESSION; METFORMIN; PROTECTS; AGONIST; MODEL;
D O I
10.1590/1414-431X20132818
中图分类号
Q [生物科学];
学科分类号
090105 [作物生产系统与生态工程];
摘要
Human serum paraoxonase contributes to the anti-atherogenic effect of high-density lipoprotein cholesterol (HDL-C) and has been shown to protect both low-density lipoprotein cholesterol (LDL-C) and HDL-C against lipid peroxidation. We investigated the effects of rosiglitazone on paraoxonase activity and metabolic parameters in patients with type 2 diabetes mellitus [50 patients (30 males, 20 females); mean +/- SD age: 58.7 +/- 9.2 years, body mass index: 28.2 +/- 4.1 kg/m(2)], in whom glucose control could not be achieved despite treatment with metformin, sulphonylurea, and/or insulin. The patients were given 4 mg/day rosiglitazone for 3 months in addition to their usual treatment. Serum paraoxonase activity, malondialdehyde, homocysteine, and lipid profile were measured at the time of initiation and at the end of therapy with rosiglitazone. After rosiglitazone therapy, serum levels of HDL-C, apolipoprotein A-1, and paraoxonase activity increased significantly (P<0.05) and malondialdehyde, homocysteine, lipoprotein(a), and glucose levels decreased significantly (P<0.05), but no significant changes in levels of total cholesterol and apolipoprotein B were observed. Triglyceride levels also increased significantly (P<0.05). Rosiglitazone treatment led to an improvement in glycemic control and to an increase in paraoxonase activity and HDL-C levels. Although rosiglitazone showed favorable effects on oxidant/antioxidant balance and lipid profile, further studies are needed to determine the effect of rosiglitazone on cardiovascular risk factors and cardiovascular morbidity and mortality.
引用
收藏
页码:528 / 532
页数:5
相关论文
共 29 条
[1]
SERUM PARAOXONASE ACTIVITY, CONCENTRATION, AND PHENOTYPE DISTRIBUTION IN DIABETES-MELLITUS AND ITS RELATIONSHIP TO SERUM-LIPIDS AND LIPOPROTEINS [J].
ABBOTT, CA ;
MACKNESS, MI ;
KUMAR, S ;
BOULTON, AJ ;
DURRINGTON, PN .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (11) :1812-1818
[2]
Hepatic Effects of Rosiglitazone in Rats with the Metabolic Syndrome [J].
Ackerman, Zvi ;
Oron-Herman, Mor ;
Pappo, Orit ;
Peleg, Edna ;
Safadi, Rifaat ;
Schmilovitz-Weiss, Hemda ;
Grozovski, Maria .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2010, 107 (02) :663-668
[3]
[Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc35-S011, 10.2337/dc12-s004]
[4]
Antihyperglycemic effect of a new thiazolidinedione analogue and its role in ameliorating oxidative stress in alloxan-induced diabetic rats [J].
Chaudhry, Jyoti ;
Ghosh, Narendra Nath ;
Roy, Kapil ;
Chandra, Ramesh .
LIFE SCIENCES, 2007, 80 (12) :1135-1142
[5]
The Cardiovascular Effects of Peroxisome Proliferator-activated Receptor Agonists [J].
Friedland, Sayuri N. ;
Leong, Aaron ;
Filion, Kristian B. ;
Genest, Jacques ;
Lega, Iliana C. ;
Mottillo, Salvatore ;
Poirier, Paul ;
Reoch, Jennifer ;
Eisenberg, Mark J. .
AMERICAN JOURNAL OF MEDICINE, 2012, 125 (02) :126-133
[6]
SPECTROPHOTOMETRIC ASSAYS FOR THE ENZYMATIC-HYDROLYSIS OF THE ACTIVE METABOLITES OF CHLORPYRIFOS AND PARATHION BY PLASMA PARAOXONASE ARYLESTERASE [J].
FURLONG, CE ;
RICHTER, RJ ;
SEIDEL, SL ;
COSTA, LG ;
MOTULSKY, AG .
ANALYTICAL BIOCHEMISTRY, 1989, 180 (02) :242-247
[7]
Effect of rosiglitazone on rabbit model of myocardial ischemia-rep effusion injury [J].
Gao, Xia-Qing ;
Li, Hua-Wei ;
Ling, Xue ;
Qiu, Ya-Hui ;
Gao, Yue ;
Zhang, Yang .
ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2013, 6 (03) :228-231
[8]
Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus [J].
Haffner, SM ;
Greenberg, AS ;
Weston, WM ;
Chen, HZ ;
Williams, K ;
Freed, MI .
CIRCULATION, 2002, 106 (06) :679-684
[9]
Rosiglitazone but not losartan prevents Nrf-2 dependent CD36 gene expression up-regulation in an in vivo atherosclerosis model [J].
Hernandez-Trujillo, Y. ;
Rodriguez-Esparragon, F. ;
Macias-Reyes, A. ;
Caballero-Hidalgo, A. ;
Rodriguez-Perez, Jose C. .
CARDIOVASCULAR DIABETOLOGY, 2008, 7 (1) :3
[10]
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial [J].
Home, Philip D. ;
Pocock, Stuart J. ;
Beck-Nielsen, Henning ;
Curtis, Paula S. ;
Gomis, Ramon ;
Hanefeld, Markolf ;
Jones, Nigel P. ;
Komajda, Michel ;
McMurray, John J. V. .
LANCET, 2009, 373 (9681) :2125-2135